Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, and rubella vaccine (live)
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
VaxPro (also known as M-M-RvaxPro) is a live attenuated trivalent vaccine developed by Merck Sharp & Dohme (MSD) for the active immunization against measles, mumps, and rubella. It contains the Enders' attenuated Edmonston strain of measles virus, the Jeryl Lynn (Level B) strain of mumps virus, and the Wistar RA 27/3 strain of rubella virus. The vaccine is indicated for individuals 12 months of age or older and works by stimulating the immune system to produce protective antibodies and cellular responses against these three viral pathogens. It is the European brand name for the vaccine marketed as M-M-R II in the United States.
- Brand names
- VaxProM-M-RvaxProM-M-R II
- Other names
- M-M-R VaxProMMR vaccine
02
Targets
RUBV C (Rubella virus capsid protein)
Beyond the preview
Go deeper on measles, mumps, and rubella vaccine (live).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, and rubella vaccine (live).